AmWINS

Public facts

Wholesale / MGU stop-loss distribution

Amwins Self-Funded (formerly Stealth Partner Group) wholesale agency and MGU that places and services medical stop-loss with leading carriers; $2.9B+ annual premium placements claimed.

Visit amwins.com

Overview

Amwins is not a stop-loss insurance company. Amwins Self-Funded, formerly Stealth Partner Group, is a specialized general agency that partners only with brokers, consultants, and TPAs to negotiate, implement, and manage medical stop-loss. Public stats: #1 in-force premium (vendor), $2.9B+ annual premium placements, 3,900+ employer groups, 350+ team members. Services include carrier negotiations, disclosure and compliance, premium/commission admin (licensed bonded TPA), claims management, analytics, captives, Amwins Advance (funds claims up to $5M in 24–72 hours, not limited to one carrier/TPA/PBM), Benefit Watch claim audits, and actuarial comparison of deductibles. Cost-containment products: Gene Therapy Solutions (first-dollar protection; fee on the stop-loss bill), Dialysis Management, Prescription Assistance, organ-transplant carve-out. Underwriting pages say 20+ years in medical stop-loss UW, bind authority in all 50 states, and carriers rated A or better by AM Best.

Why it matters Amwins is a primary wholesale/MGU pipe for independent stop-loss—the market, not the paper.

Target buyer: Retail brokers, consultants, and TPAs that need wholesale stop-loss placement and servicing—not employers buying paper direct from Amwins.
Pricing model: Wholesale placement; stop-loss premium set by the issuing carrier; program fees (e.g., GTS) may ride the stop-loss bill; Amwins does not publish carrier rate cards. Scale figures are vendor-reported. GTS gene-therapy costs cited as $400k–$4.25M per treatment are market context, not Amwins prices.
Availability: National
Research: Last researched 2026-08-23; Public facts category

Key features

Medical stop-loss placement and in-force management
MGU underwriting, excess-claims adjudication, and reconciliation
Amwins Advance cash-flow funding up to $5M
Gene Therapy Solutions, dialysis, PAP, transplant carve-out
Captive and alternative-risk programs
Benefit Watch medical/Rx audits
Actuarial fully-insured-to-self-funded analysis

Integrations

Multiple Amwins-endorsed stop-loss carriers (not listed on the page)
TPAs and BUCA administrators (Advance language)
PBMs (Advance not limited by PBM)

Overview

Amwins Group Benefits’ Self-Funded vertical (amwins.com) is a producer-facing wholesale and underwriting platform. Stealth Partner Group rebranded into Amwins Self-Funded as one of five Benefits solution sets (with Small to Mid-Market, Ancillary, Exclusive Programs, Retiree Healthcare).

Amwins Underwriters (separate capabilities page) describe specialty MGU services: underwriting, in-force management, excess claims, cost management, and financial reconciliation, with 50-state bind authority and A-or-better carrier partners.

Key Capabilities

Full stop-loss service model from negotiation through claims and premium admin.
Proprietary catastrophic cost-containment (GTS, DMS, PAP, transplant).
Multi-employer captives and FI-to-SF transitions.
Advance funding that is carrier/TPA/PBM agnostic (up to $5M, 24–72 hours, before full eligibility packets).
Audits and actuarial modeling.

Integrations & Ecosystem

Works with an “expansive carrier portfolio” and TPAs. Carrier names are not published on the self-funded homepage. GTS billing is designed to sit on the stop-loss invoice.

Pricing

Carrier premium plus Amwins/program fees. No public schedule.

Notes & Limitations

Employers do not buy “Amwins insurance”; they buy a carrier policy Amwins placed.
“#1 in-force premium” is an Amwins ranking claim.
Advance is a cash facility, not a substitute for stop-loss terms.

Sources

Tags: stop-loss · MGU · wholesale · Amwins · gene therapy